Hikma Strikes Deal For Celltrion’s Yuflyma

Firms Agree MENA Licensing Deal For High-Concentration Adalimumab Biosimilar

 
• By Dave Wallace
  
MENA Region Red Background Map
Hikma has once again expanded its MENA biosimilars portfolio • Source: Shutterstock

More from Biosimilars

More from Products